Adrenocortical Carcinoma with Hypercortisolism

Endocrinology and Metabolism Clinics of North America
Soraya PuglisiMassimo Terzolo

Abstract

Adrenocortical carcinoma (ACC) is a rare and aggressive tumor. ACC may be associated with different syndromes of hormone excess, most frequently Cushing's syndrome with or without hypersecretion of androgens. Recent data suggest that cortisol excess is a negative prognostic factor in advanced and localized ACC. Surgery with radical intent, when feasible, is the most effective treatment for ACC with hypercortisolism. Mitotane is the medical treatment of choice, both postoperatively and in inoperable or metastatic cases. Because of its slow onset of action, combination with other antisecretory agents (ie, metyrapone) is helpful to achieve more rapid and effective control of hypercortisolism.

Citations

Jan 5, 2020·The Journal of Clinical Endocrinology and Metabolism·Giuseppe ReimondoMassimo Terzolo
Jul 6, 2020·European Radiology·Andrea VeltriMassimo Terzolo
Feb 26, 2019·Therapeutic Advances in Endocrinology and Metabolism·Agnieszka Łebek-SzatańskaLucyna Papierska
Nov 15, 2020·International Journal of Molecular Sciences·Erika L Knott, Nancy J Leidenheimer
Apr 24, 2021·Radiology Case Reports·Bui-Van LenhPham Minh Thong
May 8, 2021·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·Alexandra Novais Araújo, Maria João Bugalho
Nov 3, 2021·QJM : Monthly Journal of the Association of Physicians·Masashi HasebeAkihiro Hamasaki

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenocortical Carcinoma

Adrenocortical carcinoma (ACC) is a rare malignancy of the adrenal cortex, associated with a generally dismal prognosis owing to its aggressive behavior. Here are the latest discoveries pertaining to this disease.